- Home
- ELS vs NBIX Comparison
ELS vs NBIX Comparison
Compare ELS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELS
- NBIX
- Stock Information
- Founded
- ELS 1992
- NBIX 1992
- Country
- ELS United States
- NBIX United States
- Employees
- ELS N/A
- NBIX N/A
- Industry
- ELS Real Estate Investment Trusts
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELS Real Estate
- NBIX Health Care
- Exchange
- ELS Nasdaq
- NBIX Nasdaq
- Market Cap
- ELS 12.4B
- NBIX 11.0B
- IPO Year
- ELS 1993
- NBIX 1996
- Fundamental
- Price
- ELS $64.32
- NBIX $115.71
- Analyst Decision
- ELS Buy
- NBIX Strong Buy
- Analyst Count
- ELS 9
- NBIX 20
- Target Price
- ELS $74.33
- NBIX $163.20
- AVG Volume (30 Days)
- ELS 1.4M
- NBIX 1.8M
- Earning Date
- ELS 04-21-2025
- NBIX 05-05-2025
- Dividend Yield
- ELS 3.09%
- NBIX N/A
- EPS Growth
- ELS 5.86
- NBIX N/A
- EPS
- ELS 1.94
- NBIX 2.96
- Revenue
- ELS $1,537,798,000.00
- NBIX $2,412,600,000.00
- Revenue This Year
- ELS $2.78
- NBIX $15.36
- Revenue Next Year
- ELS $3.87
- NBIX $16.34
- P/E Ratio
- ELS $33.16
- NBIX $39.66
- Revenue Growth
- ELS 1.94
- NBIX 21.73
- 52 Week Low
- ELS $58.86
- NBIX $84.23
- 52 Week High
- ELS $76.60
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- ELS 47.81
- NBIX 60.88
- Support Level
- ELS $63.55
- NBIX $105.45
- Resistance Level
- ELS $65.23
- NBIX $130.46
- Average True Range (ATR)
- ELS 1.37
- NBIX 4.31
- MACD
- ELS 0.10
- NBIX 1.96
- Stochastic Oscillator
- ELS 63.25
- NBIX 50.22
About ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 452 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.